09:14 AM EST, 02/24/2025 (MT Newswires) -- Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and The Health Care Select Sector SPDR Fund ( XLV ) up 0.3%.

Invivyd ( IVVD ) shares were down past 28% after the company said the US Food and Drug Administration rejected its request to expand the existing emergency use authorization for Pemgarda to include treatment of mild-to-moderate COVID-19 in immunocompromised adults and adolescents.

Summit Therapeutics ( SMMT ) stock was over 5% higher after the company said it will collaborate with Pfizer ( PFE ) on a set of clinical trials to evaluate ivonescimab, its investigational drug, in combination with several Pfizer ( PFE ) antibody drug conjugates to treat multiple solid tumors.

Entrada Therapeutics ( TRDA ) shares were up more than 5% after the company said the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.